In Vitro Selection of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Probiotic Strains for the Management of Oral Pathobiont Infections Associated to Systemic Diseases
The human oral pathobionts <i>Aggregatibacter actinomycetemcomitans</i>, <i>Streptococcus mitis</i> and <i>Streptococcus mutans</i>, in dysbiosis-promoting conditions, lead to oral infections, which also represent a threat to human systemic health. This scenario m...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/24/16163 |
| Summary: | The human oral pathobionts <i>Aggregatibacter actinomycetemcomitans</i>, <i>Streptococcus mitis</i> and <i>Streptococcus mutans</i>, in dysbiosis-promoting conditions, lead to oral infections, which also represent a threat to human systemic health. This scenario may be worsened by antibiotic misuse, which favours multi-drug resistance, making the research on pathogen containment strategies more than crucial. Therefore, we aimed to in vitro select the most promising probiotic strains against oral pathogen growth, viability, biofilm formation, and co-aggregation capacity, employing both the viable probiotics and their cell-free supernatants (CFSs). Interestingly, we also assessed probiotic efficacy against the three-pathogen co-culture, mimicking an environment similar to that in vivo. Overall, the results showed that <i>Lactobacillus</i> CFSs performed better than the <i>Bifidobacterium</i>, highlighting <i>Limosilactobacillus reuteri</i> LRE11, <i>Lacticaseibacillus rhamnosus</i> LR04, <i>Lacticaseibacillus casei</i> LC04, and <i>Limosilactobacillus fermentum</i> LF26 as the most effective strains, opening the chance to deeper investigation of their action and CFS composition. Altogether, the methodologies presented in this study can be used for probiotic efficacy screenings, in order to better focus the research on a viable probiotic, or on its postbiotics, suitable in case of infections. |
|---|---|
| ISSN: | 1661-6596 1422-0067 |